688278 特宝生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)15.64633.82822.34616.76514.907
总资产报酬率 ROA (%)12.78526.92517.97213.84811.760
投入资产回报率 ROIC (%)14.84132.27721.40016.03613.860

边际利润分析
销售毛利率 (%)93.36393.33288.91688.94889.464
营业利润率 (%)32.37932.41026.65021.95019.919
息税前利润/营业总收入 (%)30.60830.27423.03718.91817.624
净利润/营业总收入 (%)25.57926.44618.79716.00414.683

收益指标分析
经营活动净收益/利润总额(%)102.040103.762101.885102.29490.375
价值变动净收益/利润总额(%)0.6940.9671.1013.1513.483
营业外收支净额/利润总额(%)-5.373-6.254-14.328-15.441-13.715

偿债能力分析
流动比率 (X)4.0753.3203.5674.7086.724
速动比率 (X)3.3442.8573.0834.0515.857
资产负债率 (%)16.25120.35920.46918.46116.126
带息债务/全部投入资本 (%)1.6701.194-2.475-2.488-3.315
股东权益/带息债务 (%)5,673.1237,950.842-3,880.651-3,836.142-2,892.803
股东权益/负债合计 (%)515.351391.173388.546441.687520.135
利息保障倍数 (X)-255.666-132.170-84.160-196.146164.167

营运能力分析
应收账款周转天数 (天)67.98656.12547.56255.52965.105
存货周转天数 (天)475.396407.086261.874310.866366.276